- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
UK Boosts Cell and Gene Therapy with New Manufacturing Center
UK Business Secretary Greg Clark and Science Minister Sam Gyimah today opened the Cell and Gene Therapy Catapult’s (CGT Catapult) unique cell and gene therapy manufacturing center in Stevenage, UK. Backed by over £60 million ($84m) of UK Government investment from its Industrial Strategy, the center will support and develop the rapidly growing global cell and gene therapy industry in the UK while demonstrating the government’s modern Industrial Strategy in action. The center will also supply the network of world-first, UK-based Advanced Therapies Treatment Centres (ATTCs) formed as part of the government’s investment of £146 million ($204m) through its Industrial Strategy Challenge Fund in medicines manufacturing. Greg Clark commented: “We are determined to make the UK the most innovative nation in the world through our Industrial Strategy and its Grand Challenges, which is why we are investing a record £7 billion ($9.8 bn) in R&D by 2021, the highest increase in 40 years, and have committed to investing 2.4% of GDP on R&D by 2027.” For more information, visit ct.catapult.org.uk or http://www.gov.uk/innovate-uk.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
